Veru's novel covid-19 drug candidate reduces deaths by 55% in hospitalized patients in interim analysis of phase 3 study; independent data monitoring committee halts study early for overwhelming efficacy

-- independent data monitoring committee unanimously recommends that phase 3 clinical trial for sabizabulin for treatment of hospitalized covid-19 patients at high risk for ards be stopped early due to overwhelming evidence of efficacy -- -- sabizabulin treatment showed statistically significant and clinically meaningful 55% reduction in deaths compared to placebo in moderate-severe hospitalized patients (p=0.0029) -- -- sabizabulin oral daily dosing was well tolerated with a similar safety profile compared to placebo -- -- company to meet with fda to seek emergency use authorization -- --the company will host a conference call at 8:00 am et to discuss results and planned next steps --
VERU Ratings Summary
VERU Quant Ranking